Ltd today announced the completion of the acquisition to acquire Diaspa SpA''s
fermentation assets including its ongoing business in Milan, Italy, through its
wholly owned Strides Arcolab International Ltd.
Diaspa SpA has a fermentation capacity of 925 m3 and produces a
range of niche
pharmaceuticals. The facility has a long track record of EU and USFDA
and earlier this year acquired the US drug regulator''s approvals for its deferoximine.
Indian pharmaceuticals company plans additional investments at Diaspa to meet
its growing demand for captive fermentation pharmaceuticals mainly vancomycin
acquisition gives Strides immediate access to a USFDA and EU approved facility
and provides the technology leadership necessary for Strides to grow its sterile
injectable business," said Arun Kumar, vice chairman and managing director
of Strides Arcolab
group. "A significant part of Strides sterile dosage form business is based
on fermentation active pharmaceutical ingredients (APIs)."
also said the Italian company had strong technology, and product pipeline in addition
to the management bandwidth.